Sanofi licenses technology for new TB vaccine
Sanofi Pasteur has struck a licensing deal with the Statens Serum Institut of Denmark covering the use of its technology for a new tuberculosis vaccine. The pact includes SSI's Intercell IC31 adjuvant and the use of certain fusion proteins. SSI TB vaccine candidates are recombinant protein sub-units, including one currently in a Phase I clinical trial. Results from a previous study showed the SSI TB vaccine technology provided a positive immune response. TB kills two million people a year.
"This agreement is a milestone for Sanofi Pasteur," said Wayne Pisano, president and CEO of Sanofi Pasteur, which is also working to develop a vaccine against another one of the biggest global infectious disease killers--malaria. "The current medical arsenal is inadequate for fighting tuberculosis."
- read the press release
Related Articles:
New compounds in works for tuberculosis. Report
Maxygen, Sanofi Pasteur ink $24.5M vaccine deal. Report
New approach to vaccine development. Report
Be the first to comment
More stories about Malaria immune system Vaccine Technology Sanofi Pasteur Tuberculosis Tuberculosis Vaccine
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A; Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
